380 related articles for article (PubMed ID: 24574398)
21. Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent.
Grekova S; Aprahamian M; Giese N; Schmitt S; Giese T; Falk CS; Daeffler L; Cziepluch C; Rommelaere J; Raykov Z
Cancer Biol Ther; 2010 Dec; 10(12):1280-9. PubMed ID: 21124075
[TBL] [Abstract][Full Text] [Related]
22. Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1.
Sieben M; Schäfer P; Dinsart C; Galle PR; Moehler M
Int J Cancer; 2013 Jun; 132(11):2548-56. PubMed ID: 23151948
[TBL] [Abstract][Full Text] [Related]
23. Pediatric and Adult High-Grade Glioma Stem Cell Culture Models Are Permissive to Lytic Infection with Parvovirus H-1.
Josupeit R; Bender S; Kern S; Leuchs B; Hielscher T; Herold-Mende C; Schlehofer JR; Dinsart C; Witt O; Rommelaere J; Lacroix J
Viruses; 2016 May; 8(5):. PubMed ID: 27213425
[TBL] [Abstract][Full Text] [Related]
24. Oncolytic H-1 Parvovirus Hijacks Galectin-1 to Enter Cancer Cells.
Ferreira T; Kulkarni A; Bretscher C; Nazarov PV; Hossain JA; Ystaas LAR; Miletic H; Röth R; Niesler B; Marchini A
Viruses; 2022 May; 14(5):. PubMed ID: 35632759
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic implications of the enhanced short and long-term cytotoxicity of radiation treatment followed by oncolytic parvovirus H-1 infection in high-grade glioma cells.
Geletneky K; Hartkopf AD; Krempien R; Rommelaere J; Schlehofer JR
Bioeng Bugs; 2010; 1(6):429-33. PubMed ID: 21468212
[TBL] [Abstract][Full Text] [Related]
26. Virotherapy of digestive tumors with rodent parvovirus: overview and perspectives.
Akladios C; Aprahamian M
Expert Opin Biol Ther; 2016; 16(5):645-53. PubMed ID: 26855087
[TBL] [Abstract][Full Text] [Related]
27. Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells.
Solari JIG; Filippi-Chiela E; Pilar ES; Nunes V; Gonzalez EA; Figueiró F; Andrade CF; Klamt F
BMC Cancer; 2020 May; 20(1):474. PubMed ID: 32456685
[TBL] [Abstract][Full Text] [Related]
28. Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of the viral capsid.
Allaume X; El-Andaloussi N; Leuchs B; Bonifati S; Kulkarni A; Marttila T; Kaufmann JK; Nettelbeck DM; Kleinschmidt J; Rommelaere J; Marchini A
J Virol; 2012 Apr; 86(7):3452-65. PubMed ID: 22258256
[TBL] [Abstract][Full Text] [Related]
29. Oncolytic effects of parvovirus H-1 in medulloblastoma are associated with repression of master regulators of early neurogenesis.
Lacroix J; Schlund F; Leuchs B; Adolph K; Sturm D; Bender S; Hielscher T; Pfister SM; Witt O; Rommelaere J; Schlehofer JR; Witt H
Int J Cancer; 2014 Feb; 134(3):703-16. PubMed ID: 23852775
[TBL] [Abstract][Full Text] [Related]
30. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.
Marchini A; Daeffler L; Pozdeev VI; Angelova A; Rommelaere J
Front Immunol; 2019; 10():1848. PubMed ID: 31440242
[TBL] [Abstract][Full Text] [Related]
31. Anticancer effects of an oncolytic parvovirus combined with non-conventional therapeutics on pancreatic carcinoma cell lines.
Raykov Z; Georgieva PB; Angelova A; Galabov AS; Rommelaere J
Acta Virol; 2009; 53(1):57-60. PubMed ID: 19301953
[TBL] [Abstract][Full Text] [Related]
32. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients.
Liikanen I; Ahtiainen L; Hirvinen ML; Bramante S; Cerullo V; Nokisalmi P; Hemminki O; Diaconu I; Pesonen S; Koski A; Kangasniemi L; Pesonen SK; Oksanen M; Laasonen L; Partanen K; Joensuu T; Zhao F; Kanerva A; Hemminki A
Mol Ther; 2013 Jun; 21(6):1212-23. PubMed ID: 23546299
[TBL] [Abstract][Full Text] [Related]
33. Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo.
Leitner S; Sweeney K; Oberg D; Davies D; Miranda E; Lemoine NR; Halldén G
Clin Cancer Res; 2009 Mar; 15(5):1730-40. PubMed ID: 19223497
[TBL] [Abstract][Full Text] [Related]
34. Oncolytic H-1 Parvovirus Enters Cancer Cells through Clathrin-Mediated Endocytosis.
Ferreira T; Kulkarni A; Bretscher C; Richter K; Ehrlich M; Marchini A
Viruses; 2020 Oct; 12(10):. PubMed ID: 33096814
[TBL] [Abstract][Full Text] [Related]
35. Targeting STAT3 enhances NDV-induced immunogenic cell death in prostate cancer cells.
Wang X; Shao X; Gu L; Jiang K; Wang S; Chen J; Fang J; Guo X; Yuan M; Shi J; Ding C; Meng S; Xu Q
J Cell Mol Med; 2020 Apr; 24(7):4286-4297. PubMed ID: 32100392
[TBL] [Abstract][Full Text] [Related]
36. Oncolytic Newcastle disease virus induces autophagy-dependent immunogenic cell death in lung cancer cells.
Ye T; Jiang K; Wei L; Barr MP; Xu Q; Zhang G; Ding C; Meng S; Piao H
Am J Cancer Res; 2018; 8(8):1514-1527. PubMed ID: 30210920
[TBL] [Abstract][Full Text] [Related]
37. Fluorescence In Situ Hybridization (FISH) Detection of Viral Nucleic Acids in Oncolytic H-1 Parvovirus-Treated Human Brain Tumors.
Kiprianova I; Just A; Leuchs B; Rommelaere J; Angelova AL
Methods Mol Biol; 2020; 2058():295-306. PubMed ID: 31486047
[TBL] [Abstract][Full Text] [Related]
38. Immunogenic cell death after combined treatment with radiation and ATR inhibitors is dually regulated by apoptotic caspases.
Eek Mariampillai A; Hauge S; Kongsrud K; Syljuåsen RG
Front Immunol; 2023; 14():1138920. PubMed ID: 37346039
[TBL] [Abstract][Full Text] [Related]
39. STAT3 Contributes To Oncolytic Newcastle Disease Virus-Induced Immunogenic Cell Death in Melanoma Cells.
Shao X; Wang X; Guo X; Jiang K; Ye T; Chen J; Fang J; Gu L; Wang S; Zhang G; Meng S; Xu Q
Front Oncol; 2019; 9():436. PubMed ID: 31192135
[No Abstract] [Full Text] [Related]
40. Immunogenic cell death by oncolytic herpes simplex virus type 1 in squamous cell carcinoma cells.
Takasu A; Masui A; Hamada M; Imai T; Iwai S; Yura Y
Cancer Gene Ther; 2016 Apr; 23(4):107-13. PubMed ID: 26987291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
